Novavax, Inc. (NVAX) analyst actions
Rating and price-target actions on NVAX in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the NVAX overview →
2 measured NVAX analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Novavax Initiates Phase 3 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza | Press release | -1.74% | -3.63% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Novavax, Inc. (NVAX) And Encourages Stockholders to Reach Out | Press release | -0.50% | +0.40% |
Keep exploring
More NVAX: earnings → · SEC filings → · NVAX overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| EDGE THERAPEUTICS (EDGE) | 401 | -0.05% | 41% |
| Esperion Therapeutics, Inc. (ESPR) | 401 | 0.00% | 47% |
| AMEDICA CORP COMMON STOCK (AMDA) | 397 | -1.09% | 31% |
| PAIN THERAPEUTICS (PTIE) | 397 | -0.01% | 41% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.